Chimeric antigen receptor T-cell therapy: Difference between revisions
From IDWiki
Content deleted Content added
Created page with "== Background == * T cells are retrieved from a patient, genetically modified to add a chimeric antigen receptor (CAR) that is specific to the targetted cancer antigen, and r..." |
(No difference)
|
Revision as of 11:02, 1 February 2022
Background
- T cells are retrieved from a patient, genetically modified to add a chimeric antigen receptor (CAR) that is specific to the targetted cancer antigen, and reinfused into the patient following a short course of chemotherapy
- Used for relapsed or refractory B-cell acute lymphoblastic leukemia and high-grade B-cell lymphoma
| Product | Indications | Target Antigen | Survival |
|---|---|---|---|
| Tisagenlecleucel | B-ALL and high-grade B-cell lymphoma | CD19 | 76% 1-year OS in B-ALL; 8.3 month median OS in B-cell lymphoma |
| Axicabtagene ciloleucel | high-grade B-cell lymphoma | CD19 | 58% 18-month OS |
| Brexucabtagene autoleucel | mantle cell lymphoma | CD19 | 83% 1-year OS |
| Idecabtagene vicleucel | multiple myeloma | BCMA | 11.8 month media PFS |
| Lisocabtagene maraleucal | high-grade B-cell lymphoma | CD19 | 18.8 month median OS |
